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Background: Tuberculosis (TB) is a rare but known cause of acute respiratory distress syndrome (ARDS). The role of
inflammatory cytokines in the progression of ARDS in TB patients is unknown.
Objectives: In this study we investigated the possible link between the levels of inflammatory cytokines in
bronchoalveolar lavage (BAL) in patients with TB or ARDS alone or in patients with TB-induced ARDS (ARDS + TB).
Methods: 90 patients were studied: 30 with TB alone, 30 with ARDS alone and 30 with ARDS + TB. BAL was
collected by fiberoptic bronchoscopy and the concentrations of interleukin(IL)-6, CXCL8, TNF-α and IL-1β and the
amounts of total protein were measured by ELISA and bicinchoninic acid assay (BCA) methods respectively. The
correlation between disease severity measured by Murray scores, SOFA and APACHE II analysis and BAL mediators
and cells was also determined.
Results: CXCL8 levels in BAL were significantly higher in the ARDS + TB group compared to TB and ARDS alone
groups. Disease severity in the ARDS + TB group as determined by Murray score correlated with BAL CXCL8 and
neutrophils but not with IL-6, IL-1β and TNF-α concentrations. In addition, CXCL8 levels and neutrophils were
increased in non-miliary TB versus miliary TB. This difference in CXCL8 was lost in the presence of ARDS.
Conclusions: BAL CXCL8 levels were significantly higher in patients with ARDS induced by TB and could suggest
an important role of CXCL8 in the pathogenesis of this form of ARDS. This further suggests that CXCL8 inhibitors or
blockers may be useful to control the onset and/or development of these combined diseases.
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Acute respiratory distress syndrome (ARDS) is a common
disorder in the intensive care unit (ICU) and is associated
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article, unless otherwise stated.include sepsis, pneumonia and aspiration. Tuberculosis
(TB) remains a major public health problem in most of
the developing world and the emerging epidemic of ac-
quired immunodeficiency syndrome has resulted in a re-
surgence of TB throughout the world [2]. Tuberculosis is
a disease of protean manifestations with the lungs being
the most commonly involved site. Untreated pulmonary
TB carries a mortality of 50% with the most common
cause of death being extensive fibrocavitary disease and
respiratory failure [3]. Miliary tuberculosis is a life-
threatening disease caused by the haematogenous spread
of Mycobacterium tuberculosis. It also features as antral Ltd. This is an Open Access article distributed under the terms of the
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with mortality in TB patients in ICU [4] and is inversely
associated with the treatment of underlying TB in those
patients [5]. Factors contributing to the high mortality rate
in ICU include consolidation on chest radiographs, mul-
tiple organ failure [6], high Acute Physiology and Chronic
Health Evaluation (APACHE) II scores and sepsis [7]. Al-
though there have been several case reports describing the
association of ARDS and pulmonary TB [7-10], TB is
rarely recognized as a cause of ARDS. In fact, TB does not
feature in most recent reviews on ARDS [11,12]. Although
it is known that IFN-γ plays an important role in the
pathogenesis of TB infection, a complex network of other
cytokines, such as tumour necrosis factor alpha (TNF-α)
[13], CXCL8 [14-16], and IL-1β [17] are also thought to
be important in the pathogenesis of disease.
ARDS is a devastating inflammatory disease of the
lung which is characterised by the sudden onset of in-
creased pulmonary vascular permeability, pulmonary
oedema and respiratory failure. Activated neutrophils
play a major role in mediating the microvascular damage
and also contribute to lung tissue injury. Polymorpho-
nuclear (PMN) cells infiltrate the lung in significant
numbers and their persistence in the lungs is an import-
ant determinant of poor survival [18,19].
CXCL8 has been identified as one of the most signifi-
cant chemotactic factors for PMN in the blood and bron-
choalveolar lavage (BAL) fluid in patients with ARDS
[20,21]. In addition, CXCL-8 has been shown is necessary
for granuloma formation in the rabbit model of TB [22].
CXCL8 in TB-infected tissue may also have effects in
addition to its actions on chemotaxis being both anti-
apoptotic [23], and pro-angiogenic [24]. CXCL8 has also
been reported to affect intracellular pathogen survival,
promoting the survival of Chlamydia pneumoniae within
neutrophils [23], but increasing the killing of neutrophil
phagocytosed avirulent mycobacteria [25]. However, the
neutrophil is not the target cell of M tuberculosis and
there are no data suggesting that CXCL8 affects the sur-
vival of M tuberculosis. CXCL8 secretion in TB-infected
tissues is largely attributed to leukocytes. Monocytes se-
crete CXCL8 and cytokines in response to M tubercu-
losis [26-28]. CXCL-8 is also released by diverse BAL
cells including monocytes and macrophages and other
cell types, including fibroblasts [29], and the pulmonary
epithelium [30]. Interestingly, Yang et al. reported that
the absence of CXCL8 from TB pleural effusions [31].
In a series of studies, Donnelly et al. studied a hetero-
geneous group of ICU-patients with a predisposition for
ARDS due to trauma, pancreatitis or bowel perforation
[32]. Generally, ICU patients with a BAL CXCL-8 con-
centration higher than 200 pg/ml developed ARDS 6–
72 h following admission [32], whereas, only one patient
with a BAL CXCL-8 concentration lower than 200 pg/ml developed ARDS. In addition to CXCL-8, pulmonary
concentrations of IL-6, TNF-α and IL-1β were also in-
creased either during the development of, or during the
early phase of, ARDS [33-37].
Although TB is a treatable illness, there is a persistently
high mortality (69–80%) in patients with severe pulmon-
ary TB and acute respiratory failure [38,39], probably as a
result of TB not being recognised as a cause of ARDS and
acute respiratory failure [40].
Thus, in current study we aimed to investigate the
levels of BAL CXCL8 and related cytokines and cells in
TB, ARDS or in the combined condition to finding the
possible links with disease severity. We report that BAL
levels of CXCL-8 are raised in patients with ARDS + TB
and that this correlates with the severity of ARDS.
Materials and methods
TB and ARDS patients
The study was reviewed and approved by the Masih
Daneshvari Hospital Ethics Committee and was con-
ducted in accordance with the 2000 Declaration of
Helsinki. Informed consent was obtained from all pa-
tients or their accompanying adult.
Inclusion criteria included patients in ICU with ARDS,
TB or TB accompanied with ARDS [5,41]. 20 disease
controls with a negative purified protein derivative
(PPD) test were also included in the study. Patients were
included if they were at risk for ARDS and meeting pre-
defined criteria for either sepsis or severe trauma. Pa-
tients with ARDS met the following criteria according to
the Berlin classification of ARDS [41].
The percentage of ARDS patient on the Berlin cat-
egory according to PaO2/FiO2 ratio was 10% mild form,
55% moderate and 35% with severe form. The Murray
score was used to quantify the clinical severity of ARDS.
Survival was defined as discharge from hospital.
90 subjects with suspected active pulmonary TB dis-
ease, who had negative results in acid fast bacilli (AFB)
smears from sputa, and who had consequently under-
gone BAL procedure for diagnostic purposes were en-
rolled. Ventilatory strategies were similar in all patients.
Patients with a confirmed diagnosis of TB were assigned
to the TB group. If the TB patient admitted to ICU
contracted ARDS after admission the patient was
assigned to the ARDS + TB group. Exclusion criteria for
the study were patients less than 15 years of age or more
than 80 years of age and patients with known underlying
pulmonary disorders other than TB. Those who died
within the first 24 h were also excluded.
Murray score calculations
The Murray score was calculated as previously described
[42]. The Murray scoring system includes 4 criteria for the
development of ALI/ARDS: a “scoring” of hypoxaemia, a
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graphic findings, and level of Positive End Expiratory Pres-
sure (PEEP). Each criterion receives a score from 0 to 4
according to the severity of the condition. The final score
is obtained by dividing the collective score by the number
of components used. A score of zero indicates no lung in-
jury, a score of 1 to 2.5 indicates mild to moderate lung
injury. Generally a final score of more than 2.5 indicates
the presence of ARDS. In this particular study a Murray
score of ≥3 was the minimum entry criteria for the defin-
ition of ARDS.
Evaluation the APACHE score of study patients
The severity of disease was also assessed based on the
Acute Physiology and Chronic Health Evaluation (APA-
CHE) score [43-45]. The effects of age and chronic
health status are incorporated directly into the model,
weighted according to their relative impact, to give a sin-
gle score with a maximum of 71. The worst value re-
corded during the first 24 hours of a patient’s admission
to the ICU was used for each physiological variable. The
principal diagnosis leading to ICU admission was added
as a category weight. The severity of organ dysfunction
was also assessed using the Logistic Organ Dysfunction
System which was scored based on the sequential organ
failure assessment (SOFA) calculation where organ fail-
ure was defined by an SOFA score of 3 or more [31].
BAL fluid collection and differential cell counts
BAL fluid was collected by fibrotic bronchoscopy from
all the groups (TB, ARDS, TB + ARDS and patients who
underwent a BAL for another reason) with ARDS within
24 h of diagnosis being established. All the patients were
mechanically ventilated with 100% FiO2. Six aliquots
(20 mL each) of sterile normal saline were instilled and
the fluid was aspirated immediately after each instilla-
tion. The first retrieved BAL sample, reflecting a bron-
chial sample, was discarded and the remaining BAL was
pooled in ice-cold tubes and stored at −20°C. The BAL
was centrifuged at 200xg for 10 min at 4°C to obtain the
supernatant. Cell-free BAL fluid specimens were ali-
quoted and stored at −80°C until analysis. The samples
were frozen approximately 30 min after the bronchos-
copy procedure. All assays were performed at the same
time on defrosted samples. The BAL fluid was centri-
fuged (150xg, 5 min, 4°C), and the cell-free supernatant
was divided into aliquots and frozen at −80°C. BAL fluid
was filtered through sterile gauze to exclude mucus
plugs and was then centrifuged to obtain a cell pellet.
The cell pellet was washed once in 50 ml of Ca2+/ Mg2+
free Hanks' balanced salt solution (HBSS). The cells
were counted on a hemocytometer slide using a Kimura
counterstain and viability assessed by trypan blue exclu-
sion. Cytospins were performed, using 10 [4] cells perslide, and stained with May-Grunwald-Giemsa in order
to obtain differential cell counts.
Cytokines ELISA assays
BAL levels of IL-6, CXCL-8 (BD, USA), IL-1β (Invitro-
gen, USA), and TNF-α (bioscience, USA) were measured
by ELISA kits according the manufactures’ instructions.
Total protein assays
Total protein determinations were performed on BAL
samples using the Micro BCA (bicinchoninic acid) pro-
tein assay reagent kit (Pierce Biotechnology, USA) ac-
cording to the manufacturer’s instructions. In brief, each
sample was diluted 1:20 with the Working Reagent, in-
cubated at 37°C for 30 minutes before reading in a spec-
trophotometer at 562 nm. Values were compared to that
for a freshly prepared protein standard curve.
Statistical analysis
All multiple comparison tests were two-tailed. Direct
comparisons between two treatment groups were per-
formed with the unpaired Student t-test or the non-
parametric Mann–Whitney test when the data sets
were not normally distributed. Pearson’s correlation of
coefficient was used to analyze correlations between
the inflammatory mediators and the various parame-
ters measured. A p value of 0.05 or less was considered
significant. All statistical analyses were performed with
GraphPad Prism6.
Results
Severity of ARDS in patient groups
A total of 90 patients (32 females/58 male, mean age
38.8 yrs) admitted to ICU were included in the study.
Thirty patients had ARDS due to other complication
such as sepsis, pneumonia and autoimmune vasculitis,
30 had TB only and were admitted to ICU due to pneu-
monia and pneumothorax and 30 developed ARDS on
the background of TB. Eleven of these patients had mil-
iary TB which progressed to ARDS in ICU and 19 had
TB with ARDS. 20 disease controls (patients who under-
went a BAL for another reason) with a negative purified
protein derivative (PPD) test were also included in the
study as a control group. The disease control ICU pa-
tients had a variety of causes with 8/20 having an infec-
tious aetiology versus 12/20 having a non-infectious
aetiology. The mean APACHE II score, SOFA score and
Simplified Acute Physiology Score (SAPS II) at the time
of admission was estimated and recorded for each pa-
tient (see Table 1). 58 (64.4%) patients required mechan-
ical ventilation. Patients with either TB or ARDS alone
were matched and selected as control groups. The ICU
mortality rate was 32.4%. The mean survival time of the
patients with ARDS (with or without TB) who died was
Table 1 Control subjects are age-matched with a negative PPD (purified protein derivative) test
Controls ARDS TB ARDS + TB P-value
Age 42 ± 4.3 40 ± 5.8 42 ± 6.2 37 ± 7.5 P > 0.05
Male/Female 13/7 21/9 18/12 17/13 P > 0.05
Weight (kg) 70/75 69 ± 17.6 70 ± 14.8 74 ± 12.5 P > 0.56
Height (m) 163 ± 5 168 ± 12.5 170 ± 9.6 172 ± 8.5 P > 0.075
BMI 25 ± 3.3 24.1 ± 5.2 25.7 ± 7.5 21.5 ± 5.8 P > 0.45
BAL volume 25 ± 4.3% 23.5 ± 8.2 26.7 ± 7.3 28.1 ± 9.9 P > 0.05
APACHE II score 0 22.7 ± 3.9 18.5 ± 6.2 17.41 ± 5.6 P < 0.05
SOFA score 0 13.6 ± 2.7 12.32 ± 3.1 14.25 ± 2.5 P > 0.05
SAPS score 0 30.3 ± 7.2 32.5 ± 5.5 41.25 ± 12.05 P > 0.05
Abbreviations:
APACHE II Acute Physiology and Chronic Health Evaluation.
ARDS Acute Respiratory Distress Syndrome.
BAL bronchoalveolar lavage.
BMI body mass index.
SOFA Sequential Organ Failure Assessment.
SAPS Simplified Acute Physiology Score.
TB Tuberculosis.
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within the first 30 days.
The age and other demographic factors and mean
(±SD) of APACHE II, SOFA, and SAPS II scores were
compared between the three groups (Table 1). There
was no significant difference in any of the measures on
admission except for patients in the ARDS alone group
who had a significantly higher APACHE II score than
subjects in the other two disease groups (Table 1).
Patients with TB and ARDS have higher levels of BAL
CXCL-8
CXCL-8 concentrations in BAL were significantly ele-
vated in the TB alone and ARDS alone groups compared
to disease controls (patients who underwent a BAL for
another reason) and further increased in the ARDS + TB
group (Figure 1A). The concentrations of IL-6 were
similar in all groups and were significantly elevated com-
pared to the control group (Figure 1B). Similar results were
observed for the BAL concentrations of IL-1β (Figure 1C).
The concentration of BAL TNF-α was significantly greater
than control levels in the TB group and was further in-
creased in the ARDS alone and in the ARDS +TB group
(Figure 1D). There was no significant difference between
the levels of TNF-α in the TB alone group and the other
disease groups.
Patients with TB and ARDS have higher levels of BAL total
proteins
In addition, BAL total protein levels were higher than
those in control subjects in all three patient groups
(Figure 2). The levels seen in the ARDS + TB group
were the highest and these were significantly higher
than those in the ARDS alone group (P < 0.05).Patients with TB and ARDS has higher levels of
neutrophils in BAL
Differential cell counts were performed on cytospins ob-
tained from BAL fluid. In BAL, the most abundant cells
observed in the ARDS, TB and TB + ARDS groups were
neutrophils (Figure 3A) which comprised 67.8 ± 5.8%,
78.2 ± 3.0 and 91 ± 4.4% of the total cells in each sample,
respectively (Figure 3B). The numbers of BAL neutro-
phils were significantly greater between TB alone and
ARDS alone groups (P < 0.05) and between the TB alone
and ARDS + TB groups.
Macrophages were much less numerous than neutro-
phils in all these samples (7.8 ± 3%, 7.8% ± 4.1% and 5.9 ±
4% in BAL, respectively), and lymphocytes comprised only
about 2-3% of the total cells found in BAL. The remaining
cells were epithelial cells (data not shown). There were no
significant differences between the groups for any of these
cell types.
When we analysed the data according to whether the
subjects had milary or non-milary disease there was a
significant increase in BAL CXCL-8 (385.1 ± 14.8 vs 598 ±
22.6 pg/ml, p < 0.05) (Figure 4A) and neutrophilia (46.7 ±
4.1 vs 68.9 ± 2.5%, p < 0.001) (Figure 4B) in the patients
with non-milary TB compared to those with milary TB.
The significant increase in BAL CXCL-8 (608.6 ± 21.8 vs
686.5 ± 16.4 pg/ml, p = ns) (Figure 4C) was not observed
in those patients with ARDS. In contrast, the difference in
BAL neutrophils remained significant (72.0 ± 1.7 vs 85.1 ±
1.6%, p < 0.01) (Figure 4D).
Correlation of TB and ARDS with mortality of patients
There was a significant correlation between BAL CXCL-
8 levels and BAL neutrophilia but this was not main-
tained within the miliary TB and non-miliary groups.
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Figure 1 Cytokines levels in bronchoalveolar lavage (BAL) of patients with tuberculosis (TB), acute respiratory distress syndrome
(ARDS) and the combination of both TB and ARDS. BAL CXCL8 (A), IL-6 (B), IL-1β (C) and TNFα (D) levels in patients with TB, ARDS and in
combined patients were measured by ELISA as described in material and methods. Control subjects are age-matched with a negative PPD
(purified protein derivative) test. Data are presented as mean ± SEM (n = 30 in each group except for controls where n = 20). *p ≤ 0.05,
**p ≤ 0.01 and ***p ≤ 0.01 compared with control.
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severity as measured by APACHE II, Murray and SOFA
scores in patients with ARDS whether they had TB or not
(Figure 4). In contrast, BAL CXCL-8 levels only correlated
significantly with the SOFA score in patients with TB
alone (Figure 5). There was no correlation between the0
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Figure 2 The total protein content of bronchoalveolar lavage
(BAL) of patients with tuberculosis (TB), acute respiratory
distress syndrome (ARDS) and the combination of both TB and
ARDS. After obtaining the BAL fluids from TB, ARDS and
combination, the levels of total protein was determined as described
at materials and methods. Data are presented as mean ± SEM (n = 30
in each group except for controls where n = 20). *p ≤ 0.05, **p ≤ 0.01
and ***p ≤ 0.01 compared with control.BAL levels of IL-6, IL-1β and TNF-α and the APACHE II,
Murray or SOFA scores in any of the patients groups (data
not shown).
Discussion
Here we show that the levels of CXCL8, IL-6, IL-1β and
TNF-α in BAL were higher in ARDS and TB groups and
in patients with combined ARDS + TB compared to con-
trol subjects. However, only the levels of BAL CXCL8
were increased in an additive manner. In addition, we
demonstrated that there was a correlation between BAL
CXCL-8 levels and with the severity of disease in the
ARDS and the combined ARDS + TB groups. SOFA
scores correlated with BAL CXCL8 levels only in the TB
alone group. Differences in the Murray, APACHE II and
SOFA scores were not seen with BAL IL-6, TNF-α and
IL-1β levels.
TB is still one of the most important infectious dis-
eases in the world and involved a large number of ICU
patients; however the pathogenesis of ARDS induction
in TB patients has not been documented. Thus, under-
standing the mechanism(s) involved in the pathogenesis
of ARDS in TB patients is important for the develop-
ment of treatments in the future. Dysregulation of the
immune system plays an important role in the pathogen-
esis of ARDS and increased levels of CXCL8 could be an
important inflammatory mediator in this disease [3]. In
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were significantly higher in patients that progressed to
ARDS compared to those that do not. This has been
proposed to be due to acute hypoxia which can select-
ively up-regulate CXCL8 expression in macrophages [8].
CXCL8 is an important chemokine involved in neutro-
phil recruitment and has been shown to be released
from inflammatory cells, such as macrophages and neu-
trophils, and from epithelial cells in response to inflam-
matory signals in ARDS [9]. As such, the increased
levels of CXCL8 seen in ARDS alone could account for
the increased numbers of neutrophils in the lung and
lead to the damage to the respiratory system and epithe-
lial barrier associated with disease [7]. Indeed, the distal
airways of ARDS patients have greater expression of pro-
inflammatory cytokines from airway epithelial cells and
increased infiltration of macrophages and neutrophils
[10]. This highlights the role of injury to the epithelium,
particularly in the distal airway, in the pathophysiology
of ARDS [11].
In our study we found significantly higher levels of
CXCL8 and neutrophils in TB patients with ARDS than
in patients with TB or ARDS alone. Thus, our current
data suggests that TB could induce and maintain a local
inflammatory response (increased neutrophils numbers)
in the lungs. This may initiate further progression ofdownstream inflammatory pathways to induce ARDS
with high levels of BAL CXCL8 and neutrophils. Al-
though previous reports demonstrated increased con-
centrations of CXCL8, TNF-α, and IL-1β in ARDS
patients compare to non-ARDS patients [12], we found
that only CXCL8 increased additively in patients with
ARDS induced by TB compared to patients with ARDS
or TB alone. Importantly, this enhanced expression of
CXCL8 correlated significantly with the Murray score.
In order to determine whether ARDS in TB patients is
mechanistically similar whether the disease spreads by a
hematogenous or tracheobronchial route we examined
the differences between subjects with milary and non-
milary TB. CXCL8 expression was greater in the non-
milary subjects but this difference was lost in the subjects
with ARDS despite BAL neutrophil levels remaining
higher. This suggests that other neutrophil chemoat-
tractants may be involved. Further experiments will
need to be performed to determine whether this differ-
ence is maintained when far greater numbers of subjects
are examined. Currently, we hypothesise that although
differences in the local inflammatory processes in TB
occur between milary and non-milary TB, the effect of
inflammation from ARDS overcomes these local diffe-
rences suggesting that a similar inflammatory mechan-
ism occurs in all subjects.
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disease-driving mediator associated with the severity of
ARDS or at least a biomarker of disease severity. Our
current data examining BAL inflammatory mediator
levels does not clearly define the role of TNF-α and IL-
1β in ARDS although it is likely that they play a role in
this disease. IL-1β and TNF-α stimulate the synthesis
and release of CXCL8 in many cell types and TB may be
augmenting this pathway to induce ARDS in lungs. TB
may enhance the expression of CXCL8 in the airways of
ARDS patients by enhancing macrophage and neutrophil
recruitment into the alveolar and bronchial wall, which
would result in further release of pro-inflammatory cyto-
kines and enhanced CXCL8 secretion from epithelial or
other inflammatory cells. CXCL-8 may also further
propagate the recruitment of inflammatory cells and in-
duce damage to alveolar and bronchial wall producing
ARDS. This would result in an amplification loop in
these patients with TB-induced ARDS.
It is currently difficult to predict the outcome of ARDS
according to clinical severity, pulmonary function tests
or underlying inflammatory cytokines. In our study, we
correlated the severity of ARDS with elevated CXCL8
but not with other BAL cytokines. Indeed, BAL CXCL8
levels have previously been related to the pathogenesis
of ARDS, with poorer clinical outcomes and with in-
creased disease severity and APACHE score [13]. In our
study we detected a strong correlation of the Murray
score with CXCL8 but not with IL-1β and TNF-α. The
APACHE II score was also strongly correlated with
CXCL8 levels in BAL in our study contrary to our initial
hypothesis. In previous studies, the high expression of
CXCL8 is associated with characteristics of severity such
as low PaO2/FiO2 [14].
In our study, patients with ARDS with a persistent ele-
vation of BAL CXCL8 showed increased mortality in all
ARDS patients whether induced by TB or not. There
may be a causal effect since CXCL8 not only has a role
in neutrophil chemotaxis but also inhibits neutrophil
apoptosis [16]. Our study also confirms that BAL CXCL8
levels are associated with the severity of ARDS although
there is still debate as to whether a single biomarker
should be used to predict disease outcomes [15]. Together
these results indicate that CXCL8 could be of predictive
value for the severity and mortality of ARDS and more
importantly suggests that CXCL8 inhibitors may decrease
the mortality rate in these patients.
In summary, CXCL-8 concentrations are significantly
higher in ARDS induced by TB and CXCL8 may have a
pathogenic role in these combined diseases as they are
associated with increased neutrophils. A clinical trial of
CXCL8 inhibitors will determine whether CXCL8 is a
direct driver of mortality and severity of these combined
diseases and in ARDS alone. Further work needs to beundertaken to determine whether a combination of bio-
markers and clinical predictors may be superior to clin-
ical predictors alone for predicting mortality in ARDS.
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